SCHEMBL531779

SCHEMBL531779

CC1NCCN(C)C1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12084304 1.00
SCHEMBL12084235 1.00
Hydrochloric Acid SCHEMBL1191896 0.98 ATM (0.44)
Hydrochloric Acid SCHEMBL17477283 0.98 ATM (0.44)
SCHEMBL24511192 0.76
SCHEMBL24511190 0.76
SCHEMBL8486731 0.76
SCHEMBL30641034 0.76
SCHEMBL18652290 0.76
SCHEMBL8486728 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747234-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS Muna Therapeutics ApS (DK) 2026-05-27 EP claimed
WO-2025017103-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS MUNA THERAPEUTICS APS (DK) 2025-01-23 WO claimed
EP-4087572-A1 COMBINATION THERAPY FOR TREATING CANCER AstraZeneca AB (SE) 2022-11-16 EP claimed
EP-4747234-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS Muna Therapeutics ApS (DK) 2026-05-27 EP disclosed
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD SAINT LOUIS UNIVERSITY (US) 2026-05-26 US disclosed
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2025-02-20 US disclosed
WO-2025017103-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS MUNA THERAPEUTICS APS (DK) 2025-01-23 WO disclosed
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-09-10 US disclosed
CN-113544129-B Tricyclic compound preparation method and application thereof in medicine field 上海华汇拓医药科技有限公司 2024-07-23 CN disclosed
EP-4310084-A1 PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF Jinan University (CN) 2024-01-24 EP disclosed
EP-3856348-B1 PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS ALK2 AND/OR FGFR MODULATORS INCYTE CORP (US) 2024-01-03 EP disclosed
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
EP-2415767-A1 Poly (ADP-ribose) Polymerase (PARP) Inhibitors Takeda Pharmaceutical Company Limited (JP) 2012-02-08 EP disclosed
US-20110150864-A1 SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2011-06-23 US disclosed
WO-2011015652-A1 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS NOVARTIS AG (CH) 2011-02-10 WO disclosed
WO-2010111626-A2 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 WO disclosed
US-5239051-A Dehydrating aqueous mixture of sulfur source and polar organic compound, adding polyhalogenated phenylene compound, polymerizing PHILLIPS PETROLEUM COMPANY (US) 1993-08-24 US disclosed
EP-0536684-A1 Limiting the amount of water during the polymerization of phenylene sulfide polymers PHILLIPS PETROLEUM COMPANY (US) 1993-04-14 EP disclosed
US-4814443-A Preparation of hydroxyalkylpiperazinones by reacting glyoxal with hydroxyalkyldiamines THE DOW CHEMICAL COMPANY (US) 1989-03-21 US disclosed
US-4530704-A Using aqueous solution containing piperazinone or morpholinone compound THE DOW CHEMICAL COMPANY (US) 1985-07-23 US disclosed